Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | High-grade vs low-grade chemotherapy in patients with relapsed AML or MDS

Markéta Marková • 22 Mar 2022
EBMT 2022
Acute Myeloid Leukemia Myelodysplastic Syndromes Anthracycline Cytarabine

Markéta Marková, MD, PhD, Institute of Haematology and Blood Transfusion, Prague, Czech Republic, comments on the results of a study evaluating high-grade versus low-grade chemotherapy in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) as a strategy to manage relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT). Overall, results suggested that high-grade chemotherapy may lead to better remission, but Dr Marková notes that not all patients can be treated with this regimen after they relapse. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Markéta Marková

1:43
Highlights from EBMT 2022
Markéta Marková • 22 Mar 2022

Related Videos

2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals